Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P190028/S021

cobas HPV

Roche Molecular Systems, Inc. · Decision date Sep 19, 2025

FDA DECISIONP190028/S021

What did the FDA approve?

FDA records P190028/S021 as a supplement to PMA P190028, with the supplement type “Special (Immediate Track)”. The recorded decision is approval, dated Sep 19, 2025.

FDA approval order statement

cobas HPV for use on the cobas 5800/6800/8800 Systems (cobas HPV) is a qualitative in vitro test for the detection of high-risk Human Papillomavirus. This test detects the high-risk HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68 in the specimens listed below. Clinician-collected cervical specimens should be obtained using an endocervical brush/spatula or broom and placed in the ThinPrep Pap Test PreservCyt Solution. Self-collected vaginal specimens, obtained in a healthcare setting, can be tested as an alternative specimen type when cervical sampling is either contraindicated or cervical samples otherwise cannot be obtained. cobas HPV is indicated for use for routine cervical cancer screening as per professional medical guidelines, including triage of ASC-US cytology, co-testing (or adjunctive screen) with cytology, and HPV primary screening of individuals with a cervix to assess the risk for cervical precancer and cancer. Patients should be followed-up in accordance with professional medical guidelines, results from prior screening, medical history, and other risk factors
Regulatory pathway
PMA supplement
Supplement type
Special (Immediate Track)
Clinical specialty
Microbiology
Decision date
Sep 19, 2025
FDA change category
Labeling Change - Indications/instructions/shelf life/tradename

FDA source record

Regulatory record facts

Identifier
P190028/S021
Regulatory pathway
PMA supplement
Product code
MAQ
Decision code
APPR
Decision date
Sep 19, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: KIT, DNA DETECTION, HUMAN PAPILLOMAVIRUS.

Product code
MAQ
FDA device class
3

For the original device and its historical approval scope, see PMA P190028. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P190028 · Original PMA

    cobas HPV for use on the cobas 6800/8800 Systems

  2. P190028/S021 received

    Application receipt date recorded by FDA.

  3. P190028/S021 · FDA decision

    Special (Immediate Track)

Timeline entries are records held by MedtechLedger for P190028. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P190028

Product / regulatory recordCompanyPathwayDecision dateSource
Roche Molecular Systems, Inc.PMA approvalApr 3, 2020FDA
cobas HPVP190028/S020
Roche Molecular Systems, Inc.PMA supplementAug 7, 2025FDA
cobas HPVP190028/S022
Roche Molecular Systems, Inc.PMA supplementDec 31, 2025FDA
cobas HPVP190028/S025
Roche Molecular Systems, Inc.PMA supplementMar 17, 2026FDA
cobas HPVP190028/S024
Roche Molecular Systems, Inc.PMA supplementApr 23, 2026FDA
cobas HPVP190028/S023
Roche Molecular Systems, Inc.PMA supplementJun 16, 2026FDA
cobas HPVP190028/S026
Roche Molecular Systems, Inc.PMA supplementOct 27, 2026FDA

Explore the linked device profile

Other records with product code MAQ

Product / regulatory recordCompanyPathwayDecision dateSource
cobas HPVP100020/S066
Roche Molecular Systems, Inc.PMA supplementOct 27, 2026FDA
Alinity m HR HPVP230003/S019
Abbott Molecular, Inc.PMA supplementSep 2, 2026FDA
Becton Dickinson and CompanyPMA supplementAug 19, 2026FDA
Becton Dickinson and CompanyPMA supplementAug 14, 2026FDA
Alinity m HR HPVP230003/S015
Abbott Molecular, Inc.PMA supplementJul 23, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Roche Molecular Systems, Inc.

Headquarters
Not reported
Brand website
roche.com
FDA applicant address
4300 Hacienda Dr., Pleasanton, CA, 94588

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records